Literature DB >> 27154628

The emerging role of microRNAs in hypoxia-induced pulmonary hypertension.

Vahid Mohsenin1.   

Abstract

PURPOSE: The aim of this review is to discuss hypoxia-induced pulmonary hypertension (PH) and the role of microRNAs (miRNAs).
BACKGROUND: Acute global hypoxia causes pulmonary vasoconstriction and increased pulmonary arterial blood pressure. Chronic exposure to sustained or intermittent hypoxia as in high altitude residents, chronic obstructive lung disease and sleep-disordered breathing can lead to pulmonary hypertension (PH) and right ventricular dysfunction. The development of PH is a poor prognostic sign in these patients that affects both quality of life and mortality. The mechanism of PH due to hypoxia has not been fully established. However, its pathophenotype is similar to idiopathic pulmonary arterial hypertension in the form of vascular cell proliferation and aberrant vascular remodeling. MicroRNAs (miRNAs) are small non-coding RNA molecules that negatively regulate gene expression, therefore potentially regulating a host of cellular signaling pathways. Several miRNAs have been identified to be involved in hypoxia models of PH in animals, in patients with PH, congestive heart failure and myocardial infarction.
RESULTS: MiRNAs have been mechanistically linked to the control of a wide range of cellular responses-hypoxia, TGF-β signaling and inflammatory pathways-known to influence normal developmental physiology as well as regulating pulmonary arterial smooth muscle cell and endothelial cell phenotypes and their influence on pulmonary remodeling in the setting of hypoxia and pulmonary arterial hypertension (PAH). The blood levels of these miRNAs correlate with disease severity and prognosis.
CONCLUSIONS: Research on the role of these potential biomarkers will provide insight into the pathogenesis of PH and right heart failure and opportunities in therapeutics.

Entities:  

Keywords:  Hypoxic vasoconstriction; Obstructive sleep apnea; Pulmonary hypertension

Mesh:

Substances:

Year:  2016        PMID: 27154628     DOI: 10.1007/s11325-016-1351-y

Source DB:  PubMed          Journal:  Sleep Breath        ISSN: 1520-9512            Impact factor:   2.816


  109 in total

1.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

2.  Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension.

Authors:  Jared M McLendon; Sachindra R Joshi; Jeff Sparks; Majed Matar; Jason G Fewell; Kohtaro Abe; Masahiko Oka; Ivan F McMurtry; William T Gerthoffer
Journal:  J Control Release       Date:  2015-05-13       Impact factor: 9.776

3.  HIF-1 alpha-induced up-regulation of miR-9 contributes to phenotypic modulation in pulmonary artery smooth muscle cells during hypoxia.

Authors:  Fabo Shan; Junxia Li; Qing-Yuan Huang
Journal:  J Cell Physiol       Date:  2014-10       Impact factor: 6.384

4.  Morphologic changes in the muscular pulmonary arteries: relationship to cigarette smoking, airway disease, and emphysema.

Authors:  K A Hale; D E Niewoehner; M G Cosio
Journal:  Am Rev Respir Dis       Date:  1980-08

5.  Pulmonary arterial hypertension in patients with sleep apnoea syndrome.

Authors:  E Bady; A Achkar; S Pascal; E Orvoen-Frija; J P Laaban
Journal:  Thorax       Date:  2000-11       Impact factor: 9.139

6.  Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome.

Authors:  Silke Ryan; Cormac T Taylor; Walter T McNicholas
Journal:  Circulation       Date:  2005-10-25       Impact factor: 29.690

7.  A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples.

Authors:  Paola Caruso; Yvonne Dempsie; Hannah C Stevens; Robert A McDonald; Lu Long; Ruifang Lu; Kevin White; Kirsty M Mair; John D McClure; Mark Southwood; Paul Upton; Mei Xin; Eva van Rooij; Eric N Olson; Nicholas W Morrell; Margaret R MacLean; Andrew H Baker
Journal:  Circ Res       Date:  2012-06-19       Impact factor: 17.367

Review 8.  The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations.

Authors:  Seiichiro Sakao; Norbert F Voelkel; Koichiro Tatsumi
Journal:  Eur Respir Rev       Date:  2014-09

9.  Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells.

Authors:  Jalees Rehman; Dmitry Traktuev; Jingling Li; Stephanie Merfeld-Clauss; Constance J Temm-Grove; Jason E Bovenkerk; Carrie L Pell; Brian H Johnstone; Robert V Considine; Keith L March
Journal:  Circulation       Date:  2004-03-01       Impact factor: 29.690

10.  Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle.

Authors:  James West; Karen Fagan; Wolfgang Steudel; Brian Fouty; Kirk Lane; Julie Harral; Marloes Hoedt-Miller; Yuji Tada; John Ozimek; Rubin Tuder; David M Rodman
Journal:  Circ Res       Date:  2004-03-18       Impact factor: 17.367

View more
  6 in total

Review 1.  Novel Modulators of Asthma and Allergy: Exosomes and MicroRNAs.

Authors:  Beatriz Sastre; José A Cañas; José M Rodrigo-Muñoz; Victoria Del Pozo
Journal:  Front Immunol       Date:  2017-07-21       Impact factor: 7.561

2.  Effects of FHL1 and P21 on hypoxia-induced pulmonary vascular remodeling in neonatal rats.

Authors:  Yanna Du; Jianhua Fu; Li Yao; Dan Zhang; Na Liu; Xindong Xue
Journal:  Exp Ther Med       Date:  2017-08-28       Impact factor: 2.447

3.  IL-33 Initiates Vascular Remodelling in Hypoxic Pulmonary Hypertension by up-Regulating HIF-1α and VEGF Expression in Vascular Endothelial Cells.

Authors:  Jie Liu; Wang Wang; Lei Wang; Shihao Chen; Bo Tian; Kewu Huang; Chris J Corrigan; Sun Ying; Wei Wang; Chen Wang
Journal:  EBioMedicine       Date:  2018-06-18       Impact factor: 8.143

4.  MiR-193-3p attenuates the vascular remodeling in pulmonary arterial hypertension by targeting PAK4.

Authors:  Zhenhua Wu; Jie Geng; Yujuan Qi; Jian Li; Yaobang Bai; Zhigang Guo
Journal:  Pulm Circ       Date:  2020-12-10       Impact factor: 3.017

5.  MicroRNA‑153 attenuates hypoxia‑induced excessive proliferation and migration of pulmonary arterial smooth muscle cells by targeting ROCK1 and NFATc3.

Authors:  Minjie Zhao; Wei Wang; Ya Lu; Nan Wang; Delei Kong; Lina Shan
Journal:  Mol Med Rep       Date:  2021-01-26       Impact factor: 3.423

6.  FGF21 attenuates pulmonary arterial hypertension via downregulation of miR-130, which targets PPARγ.

Authors:  Meibin Wang; Lihuang Su; Junwei Sun; Luqiong Cai; Xiuchun Li; Xiayan Zhu; Lanlan Song; Jingyin Li; Shuolan Tong; Qinlian He; Mengsi Cai; Lehe Yang; Yanfan Chen; Liangxing Wang; Xiaoying Huang
Journal:  J Cell Mol Med       Date:  2022-01-06       Impact factor: 5.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.